knowledge -WSS

knowledge

author：leisure time 2025-09-27 10:00:09 - browse：1387

The human gut teems with bacteria and other colorful microbes. — NIH

One of the indignities of getting older is the way your body’s defenses against microbes begin to break down, leaving you extra vulnerable to infection. Researchers studying the ways these systems change with age refer to them collectively as “immunosenescence,” or, more poetically, the “twilight of immunity.” But even as scientific understanding of the phenomenon has grown over the past decade, the forces driving it remain murky.

One theory is that it all starts in the bone marrow, where a primitive reserve of stem cells replenishes the ranks of blood and immune cells to the tune of about 500 billion new cells every day. Some of these hematopoietic stem cells, or HSCs, are more likely to become long-lived stewards of immune memory like B cells and T cells; others are more likely to give rise to blood cells and front-line immune defenders. They all work in concert to get the balance right. As people age, though, one lineage of HSCs starts to dominate, throwing the equilibrium off-kilter.

On Wednesday, a team of scientists at Stanford University and the National Institutes of Health Rocky Mountain Laboratories reported in Nature that this age-associated imbalance in HSCs is to blame for a cascade of downstream declines in immune function. And by restoring a youthful balance of these cells with injections of antibodies, they were able to rejuvenate the immune systems of older mice — enabling them to better fend off viral attacks.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare says breakthrough device reimbursement rule to come by summer

explore

WSS

Sanofi strikes deal with Novavax, boosting the vaccine maker

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Supreme Court mifepristone arguments center on docs' right to sue

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Decaf coffee targeted by food safety group under obscure FDA rule

Wikipedia

knowledge

hotspot

Drug repurposing or repositioning? The language matters

Study: AI not yet building 'n

Cancer drug shortages should be causing more outrage

Merck drug for rare lung condition set for approval in U.S.

How one medical school became remarkably diverse

The Readout: Lenmeldy, GLP

Walensky prepares to leave CDC — and Congress — behind

Study: Adult vaccinations pay for themselves in societal benefits

Moonlake's readout produced a cash windfall. Risks remain

Merck drug for rare lung condition set for approval in U.S.

entertainment

Washington mulls new rules to avert another Change Healthcare

Study: Adult vaccinations pay for themselves in societal benefits

What nurses really want: sufficient staffing for patient care

Abortion pill case raises question: who can sue the FDA?

Primary care physicians play key roles in Alzheimer's management

Readout LOUD podcast: What to know about H5N1 bird flu

hotspot

focus

explore

entertainment